Healthcare / BiotechnologyNasdaqCM
$2.57
-0.23 (-8.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-95.2M · quality 63.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$85M
P/E
0.8x
↓EV/EBITDA
N/A
•ROE
13.7%
↑Gross Margin
66.9%
↑Debt/Equity
1.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-104.0%
FCF / Net income
-9.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $63.3M · net income $6.8M · FCF $-65.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $63.3M | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M | $45.6M | $36.6M | $26.9M | $187.6M | $16.5M | $863000.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Net Income | $6.8M | $6.8M | $-46.0M | $-60.6M | $-86.6M | $-64.7M | $-46.5M | $-40.0M | $-84.1M | $-66.9M | $-55.1M | $-48.4M | $-20.4M | $-37.2M | $-27.6M | $-36.4M | $-10.0M | $-3.7M | $-3.8M | $-2.6M |
| EBITDA | $-20.2M | $-20.2M | $-104.5M | $-135.7M | $-193.7M | — | — | — | — | $-88.6M | $-64.8M | $-50.5M | $-20.6M | $-35.8M | — | — | — | — | — | — |
| EPS | -0.07 | -0.07 | -2.69 | -8.47 | -14.55 | -11.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 66.9% | 66.9% | 63.8% | 72.9% | 59.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -111.0% | -111.0% | -192.9% | -164.7% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -47.9% | -398.7% | -5855.3% | — | — | — | — | — | — | — | — |
| Net Margin | 10.8% | 10.8% | -79.8% | -71.7% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.7% | -334.3% | -5611.6% | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 1.49 | 1.49 | 3.34 | 3.76 | 3.05 | 0.40 | 0.52 | 3.23 | 45.58 | 1.28 | 0.79 | 0.42 | 0.20 | — | — | — | — | — | — | — |
| Current Ratio | 2.49 | 2.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $-65.8M | $-65.8M | $-95.2M | $-136.3M | $-182.5M | $-121.1M | $-85.6M | $-97.3M | $-105.9M | $-82.0M | $-52.2M | $-20.7M | — | $-76.8M | $-23.2M | $-11.0M | — | — | — | — |
| Returns | ||||||||||||||||||||
| ROE | 13.7% | 13.7% | -202.3% | -269.0% | -207.5% | -59.5% | -46.4% | -152.4% | -4543.6% | -127.2% | -143.1% | -85.2% | -28.9% | -45.7% | -125.3% | -190.0% | 62.8% | 23.1% | -75980.0% | 96.2% |
| Valuation | ||||||||||||||||||||
| P/E | 0.80 | 0.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.44 | 1.44 | 2.04 | 0.87 | 1.68 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 9.7% | 9.7% | -31.8% | 11.6% | — | 50.9% | 24.5% | 36.3% | -85.7% | 1038.3% | 1809.6% | — | — | — | — | — | — | — | — | — |
| EPS Growth | 97.4% | 97.4% | 68.2% | 41.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.69 → -0.07
Residual
+36.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.